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Abstract: Papuamide A is representative of a class of marine derived cyclic depsipeptides, 
reported to have cytoprotective activity against HIV-1 in vitro.  We show here that 
papuamide A acts as an entry inhibitor, preventing human immunodeficiency virus infection 
of host cells and that this inhibition is not specific to R5 or X4 tropic virus.  This inhibition 
of viral entry was determined to not be due to papuamide A binding to CD4 or HIV gp120, 
the two proteins involved in the cell-virus recognition and binding.  Furthermore, papuamide 
A was able to inhibit HIV pseudotype viruses expressing envelope glycoproteins from 
vesicular stomatitis virus or amphotropic murine leukemia virus indicating the mechanism of 
viral entry inhibition is not HIV-1 envelope glycoprotein specific.  Time delayed addition 
studies with the pseudotyped viruses show that papuamide A inhibits viral infection only at 
the initial stage of the viral life cycle.  Additionally, pretreatment studies revealed that the 
virus, and not the cell, is the target of papuamide A’s action.  Together, these results suggest 
a direct virucidal mechanism of HIV-1 inhibition by papuamide A.   We also demonstrate 
here that the other papuamides (B-D) are able to inhibit viral entry indicating that the free 
amino moiety of 2,3-diaminobutanoic acid residue is not required for the virucidal activity. 
 
Keywords: HIV; papuamide A; cyclic depsipeptide; entry inhibitor; marine metabolite. 
 
1. Introduction  
 
Marine organisms have proven to be an excellent source of biologically active compounds against 
human immunodeficiency virus (HIV) [1, 2].  One class of molecules with potent cytoprotective 
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activity consists of structurally similar cyclic depsipeptides isolated from sponges.  These marine 
metabolites exhibit potent inhibition of HIV induced T cell death in vitro with selectivity indexes (SI, 
effective dose divided by the cytotoxic dose) ranging from 3 to 29.  Included in this group are: 
neamphamide A (SI=9.29) [3, 4], callipeltin A (SI=29) [4, 5], mirabamides A-D (SI ranging from 3-
13) [6] and papuamide A and B (SI=21 for both) [4, 7].  (Chemical structures provided in Fig. 1.)  The 
mirabamides are the most recently discovered of this group and have been reported to inhibit HIV-1 
envelope mediated cell-cell fusion in a recombinant vaccinia virus fusion assay [6]. 
 
Figure 1. Chemical structures of neamphamide A, callipeltin A, mirabamides A-D and 
papuamides A-D. 
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Problems associated with current therapeutic treatments and the emergence of drug resistant HIV 
strains [8] establishes the need for new therapeutic treatments.  Agents which inhibit viral entry are 
particularly sought after because they can prevent infection.  HIV entry is often described as a three 
stage process: attachment of the virus to the target cell, co-receptor binding, and fusion of the virus and 
cell membranes.  Virus attachment is generally through HIV gp120 recognition and binding to the host 
cell receptor, CD4 [9, 10].  Once the virus is attached to the cell, gp120 will undergo conformational 
changes exposing a new epitope which then interacts with a cellular chemokine co-receptor [11-13], 
typically either CCR5 or CXCR4.  After this dual receptor interaction has taken place, gp120 and gp41 
will undergo further conformational changes exposing the extracellular region of gp41[12-16].  The N-
terminal region of gp41 contains what has been called a fusion peptide that inserts itself into the cell 
membrane [17].   Two helical regions of gp41 fold upon each other, bringing the virus and cellular 
membranes into close proximity.  The resultant free energy change from this structural rearrangement 
is thought to be sufficient for lipid mixing and fusion of the two membranes to occur, thus allowing the 
viral core to enter the host cell [18-20].   Compounds that inhibit any stage of this entry process may 
not only be useful for the treatment of HIV/AIDS infected individuals, but also have the potential to be 
used as microbicides in the absence of a vaccine.   
The structural uniqueness of natural product metabolites often leads to the identification of new 
targets in the treatment of diseases and novel inhibitors of viral entry are a much desired class of drugs.  
Therefore, we investigated the mechanism by which papuamide A protects against HIV induced 
cytopathicity.  In the present study, papuamide A’s ability to inhibit HIV entry is demonstrated.   
Papuamide A is shown to target the virus and this virucidal mechanism is investigated.  In addition, 
papuamides B, C and D are shown to also inhibit HIV entry. 
 
2. Results  
 
2.1 Inhibition of viral entry by papuamide A.   
 
Investigation of papuamide A’s ability to inhibit HIV induced T cell death lead to the testing of 
papuamide A’s ability to inhibit HIV entry in the virion based fusion assay developed by Cavrois et al. 
[21].  This assay quantifies viral entry using the chimeric protein BlaM-vpr, β-lactamase linked to vpr, 
which is readily incorporated into virions produced by co-transfection with proviral DNA.  Initial 
analysis was performed using an X4 tropic virus (virus that infects cells expressing CXCR4), produced 
by co-transfection with HIV-1NL4-3 proviral DNA, to infect HeLa T4+ cells expressing CXCR4.  Fig. 
2a shows representative microscope images of this assay for control cells (non-infected cells fluoresce 
green), HIV infected cells (infected cells fluoresce blue) and infected cells treated with papuamide A 
(showing a decrease in the presence of infected cells due to inhibition of viral entry).  Fig. 2b graphs 
the results from this experiment and shows that papuamide A at a concentration of 710 nM inhibited 
approximately 80% of viral entry.  Controls used included C34 (a fusion inhibitor) which effectively 
blocked viral entry and AZT (a reverse transcriptase inhibitor) which did not prevent viral entry as 
expected.  To determine if this activity was X4 tropic specific, the ability of papuamide A to inhibit a 
R5 tropic virus (virus that infects cells expressing CCR5) was evaluated using HIV-1NL(AD8), to infect 
the TZM-bl cells, HeLa T4+ cell line expressing CCR5.  Papuamide A effectively inhibited the entry Mar. Drugs 2008, 6                                                  
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of the R5 tropic virus in a dose dependant manner (Fig. 2c).  The dose response curve provides an 
EC50 (50% effective concentration) of approximately 114 nM (Fig. 2c).  This potent effective 
concentration is similar to the EC50  of 71 nM obtained for papuamide A protection against HIV 
induced cell death determined using the cytoprotection 3-(4,5-dimethylthiazol-2-yl)-
2,5diphenltetrazolium bromide (MTT) based assay of Kiser and colleagues [22] established in our 
laboratory (data not shown).  
 
Figure 2a.  Representative fluorescence microscope images of the virion based fusion assay.  
Panels show uninfected green cells (Control), the presence of infected blue cells (NL4-3 HIV) 
and a reduction of infected blue cells in the presence of a viral entry inhibitor (Pap A). 
 
       
 
 
Figure 2b. Inhibition of NL4-3 (X4 tropic virus) entry in the presence of papuamide A (Pap 
A), the known fusion inhibitor C34 and reverse transcriptase inhibitor azidothymidine (AZT) 
at final concentrations of 710 nM, 233 nM and 18 μM, respectively.  Control represents 
uninfected cells and NL4-3 HIV represents untreated infected cells.  Viral entry is reported as a 
fluorescence ratio calculated from the amount of blue versus green fluorescence, normalized to 
control.  Results graphed as the mean ± standard error, n≥4.   Fluorescence ratio was 
significantly different (p < 0.05) from control (*) or from untreated HIV infected cells (a). 
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Figure 2c. Dose dependent inhibition of NL4(AD8) (R5 tropic virus) entry by papuamide A.  
Papuamide A was tested at concentrations of 710, 533, 355, 178, 88.8 and 43.4 nM.  Panel A 
shows the dose dependent inhibition of viral entry and panel B is a dose response curve 
generated from the same data normalized to indicate percent viral entry.  Data is representative 
of experiments with similar results repeated twice and is graphed as the mean ± standard error, 
n≥3.  Fluorescence ratio was significantly different (p < 0.05) from control (*) or from 
untreated HIV infected cells (a). 
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2.2 Papuamide A does not show significant binding to either sCD4 or gp120.   
 
The lack of tropism specificity demonstrated above suggested that the chemokine co-receptors 
(CXCR4 and CCR5) and the co-receptor binding domain of gp120 are not the targets of papuamide A 
inhibition.  However, the initial step of HIV entry, binding of gp120 to CD4, is thought to be similar 
regardless of viral tropism, therefore, the ability of papuamide A to interact with CD4 or gp120 was 
assessed.  Successful biotinylation of papuamide A without a significant loss of activity was achieved 
(data not shown) and the biotinylated papuamide A was utilized to quantify binding of sCD4 or gp120 
by surface plasmon resonance (SPR).  Fig. 3 shows the observed binding response (response in RU 
measured by the instrument) versus the expected binding response (see formula and explanation 
below) for sCD4 and gp120 with papuamide A.  SPR binding responses for both proteins were 
determined not to be significant because the observed response was 600 times lower than the 
calculated expected response for sCD4 at the maximum concentration tested, and the observed 
response for gp120 was 54 times lower than the calculated expected response at the maximum 
concentration tested.  Papuamide A was shown to interact with a positive control binding peptide, as 
expected in this system. 
Values used to determine the expected response are in Table 1.  The expected response at 
saturation is determined by the following formula:  MWA
MWL
LCR
× , (LCR=Ligand capture response, 
amount of papuamide A captured onto the biosensor chip; MWL=molecular weight of ligand, 
papuamide A; and MWA=molecular weight of analyte, the protein or peptide.)[23-26]  The observed 
response, determined by the BIAcore instrument detector in response units (RU), can be lower than the 
expected response if the concentration of analyte used is below the dissociation constant (KD) Mar. Drugs 2008, 6                                                  
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concentration value, KD values were calculated by the software from the binding responses obtained 
with multiple concentrations of analyte.  When this is the case, the fold difference in concentration 
values (KD/concentration of analyte used) is approximately proportionate to the fold difference in 
responses (expected response/observe response).  Therefore, to correct for the expected response at the 
maximum concentration tested, the expected response at saturation was divided by the fold difference 
in concentration values to determine the expected response at the maximum value tested. 
  
Figure 3.  Surface plasmon resonance showed papuamide A did not interact with sCD4 and 
gp120.  Graphs show the calculated expected binding response versus the observed binding 
response for papuamide A (Pap A) with sCD4, gp120 or positive control peptide binding. 
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Table 1. Values for SPR data analysis. 
  Analyte 
  sCD4 gp120  Peptide 
Molecular Weight  26,000  120,000  1898 
Expected Response at Saturation (RU)  9,743  44,968  712 
Observed Response (RU)at Maximum 
Analyte Concentration 
10 35  30 
Fold Difference of Responses  974  1284  24 
KD (μM) 0.08  2  176 
Maximum Analyte Concentration Tested 
(μM) 
0.05 0.08  5 
Fold Difference between KD and Analyte 
Concentration 
1.6 24  35 
Expected Response at Maximum 
Concentration Tested (RU) 
6089 1874  20 
Binding interactions between papuamide A and the above listed analytes were measured using surface 
plasmon resonance (SPR).  Above defined values were used for data analysis calculations.  Formulas 
provided in text. 
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2.3 Papuamide A does not exhibit virus envelope specificity.   
 
The proteins known to be critical for the initial stage of virus attachment to the cell do not 
appear to be the targets of papuamide A.  This finding lead to the investigation of a more general 
mechanism of viral entry inhibition.  Inhibition of infection was evaluated using multiple pseudotype 
viruses (engineered HIV virions bearing various envelope glycoproteins).  CEM-SS, a human T4 
lymphoblastoid cell line, was used for all infections except for those using pseudotype virus expressing 
JRFL, which requires the presence of CCR5.  For the JRFL pseudotype virus experiments, CEM.NKR-
CCR5, a CEM derived cell line expressing CCR5, was used.  Pseudotype viruses were produced by 
co-transfection of envelope glycoprotein plasmid and an env-defective HIV vector, DHIV-3-GFP, [27] 
which contains a green fluorescence protein (GFP) reporter gene in place of nef  (this allows for 
quantification of HIV infection by flow cytometry).  Papuamide A was tested at a concentration of 
174nM which was previously determined to inhibit approximately 50% of infection in this system 
(data not shown).   
First, the ability of papuamide A to inhibit infection in this system was confirmed using viruses 
expressing LAI (X4 tropic) or JRFL (R5 tropic) envelope proteins (Fig. 4).  This lack of viral tropism 
specificity was consistent with that observed in the virus entry inhibition studies above.  Next, the 
defective HIV-GFP virus was pseudotyped with envelope glycoproteins from either vesicular 
stomatitis virus (VSV) or amphotropic murine leukemia virus (aMLV), and the sensitivity to 
papuamide A inhibition was tested.  Papuamide A effectively inhibited infection by these pseudotype 
viruses (Fig. 4).  These results confirm that papuamide A does not act by inhibiting the recognition and 
attachment of the virus to the cell and also suggests that papuamide A’s activity in not selective for 
gp41 mediated fusion.  VSV and aMLV envelopes result in the virus entering through a receptor 
mediated endocytic pathway [27-30] and through the PIT-2 sodium phosphate co-transporter mediated 
pathway [31, 32], respectively. 
 
Figure 4.  Papuamide A inhibits infection by pseudotype viruses presenting LAI (X4 tropic), 
JRFL (R5 tropic), vesicular stomatitis virus (VSV) or amphotropic murine leukemia virus 
(aMLV) envelope glycoproteins. Black columns indicates no papuamide A added, white 
columns indicate infection in presence of 178 nM papuamide A.  Data is graphed as the mean 
± standard error, n≥3.  Percent infection was significantly different (p < 0.05) between infected 
cells that were not treated and infected cells treated with papuamide A (*). 
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The pseudotype virus assay described above is a single round infectivity assay that can detect 
inhibition of early viral life cycle events.  To confirm the activity of papuamide A in the pseudotyped 
virus system was due to inhibition of the initial viral entry steps, time delayed addition studies were 
performed.  Compounds which are active during the entry process of the viral life cycle show a strong 
time dependency in their effectiveness.  This is illustrated in Fig. 5a with the controls C34, an inhibitor 
of fusion, and AZT, a reverse transcriptase inhibitor.  C34 showed a significant decrease in 
effectiveness when addition was delayed by 1 hour, with an even greater loss of activity when addition 
was delayed 2 hours.  The profile of AZT showed no difference in activity when added 1 hour after 
infection, and only a minor loss of activity when added 2 hours after infection.  Papuamide A’s profile 
(Fig. 5b) was similar to that of C34, indicating the observed activity is at the initial stages of the viral 
life cycle.  A similar loss of inhibition due to delayed addition was also observed for pseudotype virus 
expressing VSV envelope glycoprotein when compared to pseudotype virus expressing an HIV 
envelope glycoprotein (Fig. 5c).  
 
2.4 Papuamide A interacts directly with the virus, not the target cell, to inhibit infection.   
 
Current FDA approved inhibitors of viral entry and the majority of those under investigation 
target CD4, gp120, the chemokine co-receptors, or gp41 mediated fusion.[33]  Papuamide A’s 
inhibition of viral entry has been shown to be independent of these proteins and appears to be novel in 
its mechanism.  To further evaluate papuamide A’s mechanism, pretreatment studies were performed 
to determine if papuamide A was interacting directly with the virus or the target cell.   
 
Figure 5a. Time dependent inhibition of infection by controls C34 (233 nM) and AZT (3.7 μM).  
CEM-SS cells were infected with DHIV-3 pseudotype virus expressing an X4 tropic envelope 
(IIINL4) and treated with control drugs at the stated time points.  DHIV-3 represents infected 
cells treated with vehicle. Data is graphed as average with range from duplicate determinations.  
Percent infection was significantly different (p < 0.05) between infected cells that were untreated 
and those treated (*), between 0 hour and other timepoint treatments (a), and between 1hour and 
2 hour timepoint treatments (b).                                                                   
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Figure 5b.  Time dependent inhibition of infection by papuamide A.  CEM-SS cells were 
infected with DHIV-3 pseudotype virus expressing IIINL4 envelope and treated with 
papuamide A (178 nM) at the stated time points.  DHIV-3 represents infected cells treated with 
vehicle. Data is graphed as the mean ± standard error, n≥3. Percent infection was significantly 
different (p < 0.05) between infected cells that were untreated or treated with papuamide A (*), 
between 0 hour and other timepoint treatments (a), and between 1hour and 2 hour timepoint 
treatments (b). 
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Figure 5c.  Time dependent inhibition of IIINL4env versus VSV-G pseudotype virus by 
papuamide A.  Papuamide A, 178 nM, was added to IIINL4env and VSV-G pseudotype virus 
at the time of infection, 0 hr., (black bars) and two hours (grey bars) after virus addition tested 
alongside untreated infected cells (white bars).  Data is graphed as the mean ± standard error, 
n≥3 for virus pseudotyped with HIV IIIenv and as average with error bars from duplicate 
determinations for virus pseudotyped with VSV envelope.   
DHIV-3 IIINL4
Pap A 0 hr.
Pap A 2 hr.
0
10
20
30
40
50
60
70
80
90
100
110
*
*a
N
o
r
m
a
l
i
z
e
d
 
P
e
r
c
e
n
t
 
I
n
f
e
c
t
i
o
n
DHIV-3 VSV
Pap A 0 hr.
Pap A 2 hr.
0
10
20
30
40
50
60
70
80
90
100
110
*
a
N
o
r
m
a
l
i
z
e
d
 
p
e
r
c
e
n
t
 
i
n
f
e
c
t
i
o
n
 
 
In the virion fusion assay, cells were incubated with papuamide A for 2 hours prior to infection.  
Papuamide A containing medium was removed followed by two washes.  This pretreatment protocol 
did not result in inhibition of viral entry demonstrating that papuamide A does not have an irreversible Mar. Drugs 2008, 6                                                  
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effect on the cell (Fig. 6a).  Preincubation of the cells with papuamide A overnight also failed to 
inhibit viral infection (data not shown).  Modification of the fusion assay was performed so that HIV 
was pretreated with papuamide A for 30 minutes prior to infection.  Virus pretreatment, followed by 
dilution of virus, resulted in a rate of inhibition similar to when papuamide A was added at the same 
time as virus (Fig. 6a).  However, in this experiment papuamide A could only be diluted, not 
completely removed from the virus and medium.  Effective removal of unbound papuamide A after 
virus incubation requires ultracentrifugation, but ultracentrifugation of HIV enveloped virus greatly 
decreases virus infectivity [34, 35].  To overcome this problem, VSV-G pseudotype virus was used for 
pretreatment studies because VSV-G pseudotype virus has been shown to retain infectivity after 
ultracentrifugation [34].  VSV-G pseudotype virus was treated with papuamide A and incubated 
overnight.  Virus was pelleted, papuamide A containing supernatant removed and pellet suspended in 
fresh medium.  Virus pretreatment with papuamide A resulted in an approximate 50% decreased 
infectivity of the virus (Fig. 6b).  This decreased infectivity was the same as that observed when 
papuamide A was added to cells at the same time as VSV-G pseudotype virus (control virus underwent 
overnight incubation with vehicle and ultracentrifugation to control for potential loss of infectivity due 
to this process).  These results indicate that papuamide A either remains stably bound in an inhibitory 
association with the virions after ultracentrifugation and washing or, alternatively, papuamide A 
inactivates the virus. 
 
Figure 6a.  Papuamide A does not inactivate the cell to inhibit viral entry.  Inhibition of NL4-3 
BlaM-Vpr virus entry was determined when 178 nM papuamide A was preincubated with 
target cells followed by washing, preincubated with virus followed by dilution, and no 
preincubation (added at the same time as virus).  Control represents uninfected cells and NL4-3 
HIV represents untreated infected cells.  Viral entry reported as a fluorescence ratio.  Data is 
graphed as the mean ± standard error, n≥3.  Response ratio was significantly different (p < 
0.05) from control (*), between HIV infected cells that were untreated or treated with 
papuamide A (a) and between papuamide A cells treated at time of virus addition (no 
preincubation) versus other papuamide A treatment protocols (b).      
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Figure 6b.  Papuamide A interacts directly with the virus. VSV pseudotype virus was 
incubated overnight with or without 178 nM papuamide A.  Non-preincubated virus, 
preincubated virus, and non-preincubated virus with papuamide A were used to infect CEM-SS 
cells.  Infection was determined by quantifying the percent of total cells expressing GFP.  Data 
is representative of experiments with similar results repeated at least twice and is graphed as 
the mean ± standard error, n≥3.  Percent infection was significantly different (p < 0.05) 
between infected cells that were untreated or treated with papuamide A (*). 
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2.5 Effect of binding phosphatidylserine 
   
Papuamide B only differs from papuamide A by one methyl group. Papuamide B has been shown to 
bind to and cause leakage of phosphatidylserine (PS) containing liposomes, but not those composed 
solely of phosphatidylcholine [36].   PS is a phospholipid normally present on the inner leaflet of the 
cell membrane, but during apoptosis the regulation of PS is altered and PS is present on the outer 
leaflet.  Callahan et al. showed PS is present in the envelopes of HIV virions and reported that binding 
of PS by Annexin V, a specific binder of PS, was able to inhibit monocyte and macrophage infection, 
but not T cell infection [37].  These results suggest that binding of PS by papuamide A may disrupt the 
viral membrane.  Therefore, the possibility of PS being the target of papuamide A’s virucidal activity 
was investigated.   
Papuamide A’s ability to bind to phosphatidylserine was observed using surface plasmon 
resonance.  Twenty percent phosphatidylserine and 80% phosphatidylcholine (PC) vesicles were tested 
alongside 100% PC vesicles.  The PS:PC vesicles exhibited binding to papuamide A while the 100% 
PC vesicles did not (data not shown).  This indicates there is a preferential binding of papuamide A to 
phosphatidylserine.  To determine if binding of PS alone was sufficient to inhibit viral entry, annexin 
V (AV) was tested in the virion based fusion assay.  AV (tested at the concentrations similar to and 
higher than that shown to inhibit HIV infection) did not have any inhibitory effect on either X4 or R5 
virus entry, while papuamide A remained active (Fig. 7a).  In addition the effect of papuamide A was Mar. Drugs 2008, 6                                                  
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unchanged in the presence of AV when tested in the pseudotype assay (Fig. 7b).  The results suggest 
that PS binding does not appear to be necessary for papuamide A to block entry.   
 
Figure 7a.  Binding of phosphatidylserine alone in not sufficient enough to inhibit viral entry.  
Binding of phosphatidylserine by annexin V (AV) was assessed in the virion fusion assay 
against X4 (NL4-3) and R5 (NL(AD8)) tropic virus.  Control represents uninfected cells and 
NL4-3 or NL(AD8) HIV represents untreated infected cells.  Viral entry is reported as a 
fluorescence ratio.  Data is graphed as the mean ± standard error, n≥4.  Response ratio was 
significantly different (p < 0.05) from control (*), or between HIV infected cells that were 
untreated or treated (a). 
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Figure 7b.  Co-treatment of papuamide A with AV does not affect papuamide A’s inhibition 
of infection by HIV envelope pseudotype virus.  CEM-SS cells were infected with DHIV-3 
pseudotype virus expressing IIINL4 envelope and treated with papuamide A (Pap A, 178 nM), 
annexin V (AV, 0.1 μM), or papuamide A and annexin V.  DHIV-3 represents infected cells 
treated with vehicle. Data is graphed as the mean ± standard error, n=3.  
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2.6 Papuamides B-D inhibit viral entry 
 
  While we were limited by the amount of papuamides B-D available for testing, the ability of 
these analogs to inhibit HIV entry was determined.  Papuamide B exhibited similar inhibition of viral 
entry, approximately 80% inhibition at 710 nM, when compared to papuamide A (Fig. 8).  Papuamides 
C and D were less potent, inhibiting approximately 30% and 55%, respectively, at concentrations of 40 
and 20 fold higher (Fig. 8).   Furthermore, papuamides C and D effective concentrations were closer to 
their cytotoxic concentrations suggesting a narrower “therapeutic” window for these analogs in vitro 
(data not shown).    
 
Figure 8.  Papuamides B-D inhibit HIV entry.  Papuamides A-D were tested at the stated 
concentrations against NL(AD8) virus in the virion based fusion assay.  Control represents 
uninfected cells and NL(AD8) HIV represents untreated infected cells.  Viral entry is reported 
as a fluorescence ratio calculated from the amount of blue versus green fluorescence, 
normalized to control.  Results graphed as the mean ± standard error, n≥4.   Fluorescence ratio 
was significantly different (p < 0.05) from control (*) or from untreated HIV infected cells (a). 
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3. Conclusion   
 
In this study, we determine that the mechanism of papuamide A cytoprotection against HIV is 
through inhibition of virus entry.  Papuamide A’s ability to inhibit both X4 and R5 tropic virus was 
similar to that recently published for the mirabamides, which were shown to inhibit fusion [6].  Further 
work shows that papuamide A inhibition does not target the key proteins involved in the viral entry 
process.  Instead papuamide A works through a direct interaction with the virus and its virucidal 
activity appears to be independent of the type of envelope glycoprotein expressed.  Phosphatidylserine 
(PS) a phospholipid present on the viral membrane has been proposed to be the target of papuamide B.  
Data presented here shows that while papuamide A does selectively bind PS, binding of PS alone is 
not sufficient to block viral entry.   Mar. Drugs 2008, 6                                                  
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Papuamide A’s activity may be representative of the group of marine depsipeptides shown to inhibit 
HIV induced cytopathicity.  Papuamide A shares many chemical features with this group including an 
aliphatic tail, depsipeptide cyclization, a 3,4-dimethylglutamine residue and an available tyrosine 
hydroxyl (glycosylated in the mirabamides).   Previously anti-HIV activity was reported for 
papuamides A and B.  Here we show that papuamide C and D inhibit HIV entry as well, although less 
potently than A and B.  This suggests that the free amino group of the 2,3-aminobutanoic acid residue 
of papuamides A and B is not required although it may contribute to the proposed virucidal activity of 
these compounds. 
A proposed model for the mechanism of virucidal activity for these compounds can be based upon 
the membrane targeting mechanism proposed for a antifungal sterol dependent lipopeptide [38].    In 
this model, the lipopeptide has an aliphatic tail which inserts itself into the fungal membrane.  The 
interaction is then stabilized through tyrosine binding to sterol present in the fungal membrane [38].  
Cholesterol is a major component of the HIV viral membrane due to budding of the virus from cellular 
membrane microdomains rich in cholesterol and sphingolipids [39-41].  Common attributes of 
papuamide A and the other active depsipeptides include a tyrosine available to interact with 
cholesterol and a hydrophobic tail which could insert into the viral membrane.  We hypothesize this 
could lead to disruption of the viral membrane resulting in a virucidal effect.  Cooperative binding to 
PS may or may not contribute to papuamide A’s targeting of the viral membrane over the cellular 
membrane.    
 
4. Experimental Section 
 
4.1  Cells lines 
 
The following cell lines were obtained through the AIDS Research and Reference Reagent 
Program: HeLa T4+, a human cervical epithelial carcinoma (HeLa) cell line rendered CD4+ by 
retrovirus-mediated gene transfer [42]; TZM-bl, a HeLa cell line stably expressing CD4 and CCR5 
with β-galactosidase and luciferase reporter genes [43-45]; CEM-SS, a human T4 lymphoblastoid cell 
line [46, 47]; and CEM.NKR-CCR5, a human T4 lymphoblastoid cell expressing CCR5 [48, 49].  
These cell lines were contributed by: Dr. Richard Axel; Dr. John C. Kappes, Dr. Xiaoyun Wu and 
Tranzyme Inc.; Dr. Peter L. Nara; and Dr. Alexandra Trkola, respectively.  The HeLa T4+ and TZM-bl 
cell lines were maintained in Dulbecco’s modified Eagles medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS) and the CEM-SS and CEM.NKR-CCR5 cell lines maintained in RPMI 
supplemented with 10% FBS and 200 μM L-glutamine.  The human embryonic kidney (HEK) cell line 
transformed to express the large T antigen, 293FT (Invitrogen, Carlsbad, CA), was maintained in 
DMEM, 10% FBS and 200 μM L-glutamine. 
 
4.2  Plasmids 
 
The pAdVAntage plasmid was purchased through Invitrogen (Carlsbad, CA).  Dr. Eric O. Freed at 
the National Institutes of Health (NIH) kindly provided pNL4-3 and pIIINL4env [50].  pNL(AD8) was 
obtained through the AIDS Research and Reference Reagent Program, contributed by Dr. Eric O. Mar. Drugs 2008, 6                                                  
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Freed [51].  The plasmid pSCA was kindly provided by Paula M. Cannon, University of Southern 
California [52].  The following plasmids have been described elsewhere, pMM310 [21],pDHIV-3 [27], 
pHCMV-VSVG [34], pLET-JRFL [53], and pLET-LAI [53, 54].  
 
4.3  Drugs 
 
Papuamides A-D were the generous gift of Drs. David Williams and Raymond Andersen from the 
University of British Columbia [7].  Papuamide A was dissolved in 50:50, H2O:MeOH at a stock 
concentration of 10 mg/ml.  Azidothymidine (AZT) was purchased from Sigma-Aldrich (St. Louis, 
MO) and kept at a stock concentration of 10 mg/ml in DMSO.  HIV-1 IIIB C34 Peptide (C34) was 
obtained through the AIDS Research and Reference Reagent Program contributed by the Division of 
AIDS, NIAID [55].  C34 was dissolved in H2O at a concentration of 1 mg/ml.  All concentrations of 
drugs used in text and figures are provided as final concentration in culture. 
 
4.4  Virion based fusion assay.   
 
The fusion assay used was developed by Cavrois et al. [21]. Briefly, production of virus was 
accomplished by co-transfection of 20 μg of pMM310 (plasmid encoding β-lactamase linked to Vpr, 
BlaM-Vpr) [56],10 μg pAdVAntage (Invitrogen, Carlsbad, CA); and 60 μg pNL4-3(X4 tropic proviral 
DNA) [50] or pNL(AD8) (R5 tropic proviral DNA) [51] into 293FT cells using standard calcium 
phosphate transfection.  Virus was collected after 48 hours and titered using the RETROtek p24 
ELISA kit (ZeptoMatrix, Buffalo, NY).  HeLaT4 or TZM-bl cells, 200μL at a concentration of 1 X 10
5 
cells/mL, were plated into 96 well, black walled, flat bottom plates and placed in a 37ºC, 5% CO2 
humidified incubator overnight for attachment.  Medium was aspirated and 200 μL of medium 
containing virus, at a predetermined p24 concentration of 200 ng/mL, was added with test compounds 
or vehicle.  Cells were incubated at 37ºC, 5% CO2 for 2 hours.  Virus was aspirated off and cells rinsed 
twice with room temperature CO2 independent medium (Invitrogen, Carlsbad, CA).  Cells were then 
loaded with CCF2-AM fluorescent substrate (Invitrogen, Carlsbad, CA) according to manufacturer’s 
protocol.  Cells were incubated, protected from light, for 1 hour at room temperature and washed twice 
with room temperature CO2 independent medium.  Next, 200 μL of room temperature CO2 
independent medium supplemented with 10% FBS and 2.5mM probenecid (Sigma-Aldrich, St. Louis, 
MO) was added and the reaction was allowed to develop for 5-7 hours.   
When fusion occurs, β-lactamase (BlaM) present in the virus cleaves the CCF2-AM substrate.  This 
cleavage results in a change of the fluorescence emission from green to blue.  Images of the cells were 
taken with a fluorescent microscope equipped with the appropriate filter set, Excitation filter 405±10 
nm, Dicroic mirror 425, Emission Filter (blue) 460±20 nm, and Emission Filter (green) 530±15 nm.  
Using ImageJ, an image software program provided by NIH, the amount of green and blue 
fluorescence was determined.  To quantify the observed fusion, a fluorescence ratio was calculated by 
dividing the amount of blue fluorescence by the amount of green fluorescence.  This value was then 
normalized to the non-infected control by dividing the calculated values by the average control value. 
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4.5  Papuamide A-protein binding interactions 
 
Binding interactions were quantified by surface plasmon resonance (SPR).  Studies were performed 
at the University of Utah Protein Interactions facility on a BIAcore 3000 instrument.  Briefly, 
papuamide A was biotinylated using the EZ-Link Sulfo-NHS-LC-LC-Biotin reagent (Pierce 
Biotechnology, Rockford, IL) with reaction products purified by reverse phase high performance 
liquid chromatography (HPLC).  Biotinylation was confirmed by mass spec and presumed to target the 
free amine of the 2,3-diaminobutenoic acid.  Biotinylated papuamide A was captured onto a chip with 
a carboxymethylated dextran matrix preimmobilized with streptavidin.  Analytes were then flowed 
over the chip in hepes buffered saline (HBS) running buffer containing 1 mg/mL bovine serum 
albumin to reduce nonspecific binding.  Soluble CD4 (sCD4) [57] and gp120 were obtained through 
the AIDS Research and Reference Reagent Program, contributed by Progenics Pharmaceuticals, Inc. 
and Division of AIDS, NIAID, NIH, respectively.  A papuamide A positive control binding peptide 
was identified from a library of peptides (Catalog #6405, AIDS Research and Reference Reagent 
Program, NIH) contributed by Division of AIDS, NIAID, NIH.  Stock concentration of 5 μM for 
sCD4, 8.3 μM for gp120 and 500 μM for the peptide were diluted 1/100 followed by three serial 
dilutions in HBS for testing.  Binding responses reported as an arbitrary resonance unit (RU).  Data 
analyzed using the SCRUBBER software, developed by the University of Utah Protein Interactions 
Facility. 
 
4.6  Pseudotype virus assay 
 
The production of pseudotype virus was accomplished by co-transfection of 30 μg of pDHIV-3 and 
15 μg envelope plasmid by calcium phosphate mediated transfection of 293FT cells.  pDHIV-3 [27] is 
a plasmid which encodes for all HIV proteins except envelope and nef and contains a green 
fluorescence protein (GFP) reporter gene in place of nef.  Envelope glycoprotein plasmids used 
included:  pSCA [52], amphotropic murine leukemia virus glycoprotein (aMLV); pHCMV-VSVG 
[34], vesicular stomatitis virus glycoprotein (VSV); pLET-JRFL [53], a R5 tropic HIV envelope 
glycoprotein; and, pLET-LAI [53, 54] and pIIINL4env [50], X4 tropic HIV envelope glycoproteins.   
For inhibition studies, a 1.5 mL aliquot of pseudotype virus, with or without 178 nM 
papuamide A, was added to 2.5 x 10
5 CEM-SS or CEM.NKR-CCR5 cells in microfuge tube.  Cells 
underwent a spinoculation at 1,700 x g for 2 hours at 25ºC.  Virus was aspirated and cells resuspended 
in 1mL RPMI, 10%FBS and plated into a 12 well culture plate.  Cells were incubated for 48 hours at 
37ºC, 5% CO2 after which they were analyzed by flow cytometry.  Infection rates were normalized so 
that the number of GFP expressing cells in the HIV infected control equaled 100. 
 
4.7  Flow Cytometry 
 
Flow cytometry was performed using a FACScan instrument (Becton Dickinson, Franklin Lakes, 
NJ).  Cells were pelleted by centrifugation at 1,700 x g, washed with fluorescence-activated cell sorter 
(FACS)
 buffer (2% fetal bovine serum and 0.02% sodium azide in PBS)
 and resuspended in FACS 
buffer for analysis.    The flow cytometer was set to analyze a total of 10,000 cells, gating for GFP Mar. Drugs 2008, 6                                                  
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producing cells.  Analysis was performed by Cell Quest Alias software (BD Biosciences, San Jose, 
CA).  Percent of total cells expressing GFP indicates percent cells infected.  Background counts were 
averaged and subtracted from the infected and treated cell values. 
 
4.8  Time dependent inhibition of infection 
 
Infection of CEM-SS cells with pseudotype virus expressing IIINL4env (X4 tropic envelope) or 
VSV envelope was performed as described above with the exception of 0.5 mL of virus added with 1 
mL of fresh medium.  This allows for consistency between treatments because medium does not have 
to be changed after spinoculation.  Initial time-dependency experiments were performed with 
IIINL4env pseudotype virus.  Papuamide A (178 nM), AZT (3.7 μM) or C34 (233 nM) was added at 0, 
1 and 2 hours after virus addition.  To determine effect of cell pretreatment, cells were treated with 
papuamide A overnight, pelleted by centrifugation at 1,700 x g and papuamide A containing medium 
aspirated.  A second experiment with delayed addition of papuamide A to VSV and IIINL4env 
pseudotype virus was also performed. 
 
4.9  Assessment of papuamide A preincubation on viral fusion 
 
HeLa T4 cells were infected with NL4-3 BlaM virus and treated with 710 nM papuamide A, 
following these three protocols:  Virus pretreated with papuamide A for 30 minutes at room 
temperature prior to dilution and addition to the cells; Cells pretreated with papuamide A for 2 hours 
followed by aspiration of papuamide A containing medium and addition of virus; Virus and papuamide 
A added to the cells at the same time. 
 
4.10  Effect of VSV pseudotype virus pretreatment 
VSV pseudotype virus was incubated with or without 178 nM papuamide A overnight in a 37ºC, 
5% CO2 incubator.  Virus was centrifuged at 25,000 x g for 2 hours at 4ºC to pellet the virus.  Virus 
was resuspended in fresh RPMI, 10% FBS medium.  Non-pretreated virus, non-pretreated virus plus 
178 nM papuamide A and virus pretreated with 178 nM papuamide A were then used to infect CEM-
SS cells by spinoculation and infectivity determined by flow cytometry after 24 hours. 
 
4.11  Analysis 
 
Image J (NIH) was used to quantify fluorescence from microscope images.  Prism software 
(GraphPad Software) was used to generate and analyze dose response graph.  Statistical analysis was 
performed using the paired Student t-test with a significance level at p < 0.05. 
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